Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression

Endocrine-Related Cancer

Volumn 21, Issue 6, 2014, Pages 891-902

  Kim, Min Hee ^a   Bae, Ja Seong ^a   Lim, Dong Jun ^a   Lee, Hyoungnam ^a   Jeon, So Ra ^a   Park, Gyeong Sin ^a   Jung, Chan Kwon ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Mutation; Papillary thyroid carcinoma; Proteins BRAF; Proto oncogene

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; CANCER STAGING; DISEASE COURSE; FEMALE; FOLLOW UP; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; THYROID TUMOR; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84919636124     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0147     Document Type: Article

References (33)

1. Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, Dobrovic A, Cebon J & Behren A 2013 Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Medical Genomics 6 40. (doi:10.1186/1755-8794-6-40)
2. de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A et al. 2014 High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E1530-E1538. (doi:10.1210/jc.2013-4389)
3. Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG et al. 2012 Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocrine-Related Cancer 19 779-784. (doi:10.1530/ERC-12-0239)
4. Cheng S, Serra S, Mercado M, Ezzat S & Asa SL 2011 A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clinical Cancer Research 17 2385-2394. (doi:10.1158/1078-0432.CCR-10-2837)
5. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park do J, Lee HS, Cho BY, Lee ES et al. 2006 Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clinical Endocrinology 65 660-666. (doi:10.1111/j.1365-2265.2006.02646.x)
6. Eloy C, Santos J, Soares P & Sobrinho-Simoes M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Archiv 459 265-276. (doi:10.1007/s00428-011-1133-7)
7. Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S & Ciarrocchi A 2013 Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. Journal of Clinical Endocrinology and Metabolism 98 E934-E942. (doi:10.1210/jc.2012-3930)
8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. 2012 Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 366 883-892. (doi:10.1056/NEJMoa1113205)
9. Ghossein RA, Katabi N & Fagin JA 2013 Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. Journal of Clinical Endocrinology and Metabolism 98 E1414-E1421. (doi:10.1210/jc.2013-1408)
10. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G et al. 2012a The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 517-524. (doi:10.1210/jc.2011-0618)
11. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A & Vitale M 2012b A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism 97 2333-2340. (doi:10.1210/jc.2011-3106)
12. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ & Lee KY 2010 Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Modern Pathology 23 1201-1208. (doi:10.1038/modpathol.2010.116)
13. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ & Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63 588-593. (doi:10.1111/j.1365-2265.2005.02389.x)
14. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS & Hwang TS 2009 Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19 137-141. (doi:10.1089/thy.2008.0144)
15. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH et al. 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118 1764-1773. (doi:10.1002/cncr.26500)
16. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE & Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 65 4238-4245. (doi:10.1158/0008-5472.CAN-05-0047)
17. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P & Preusser M 2012 Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. American Journal of Surgical Pathology 36 844-850. (doi:10.1097/PAS.0b013e318246b527)
18. Lee JH, Lee ES & Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a metaanalysis. Cancer 110 38-46. (doi:10.1002/cncr.22754)
19. Marotta V, Guerra A, Zatelli MC, Uberti ED, Di Stasi V, Faggiano A, Colao A & Vitale M 2013 BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. Clinical Endocrinology 79 733-738. (doi:10.1111/cen.12194)
20. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS & Bae JS 2012 Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? American Journal of Surgery 203 436-441. (doi:10.1016/j.amjsurg.2011.02.013)
21. Nikiforova MN, Wald AI, Roy S, Durso MB & Nikiforov YE 2013 Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 98 E1852-E1860. (doi:10.1210/jc.2013-2292)
22. Nowell PC 1976 The clonal evolution of tumor cell populations. Science 194 23-28. (doi:10.1126/science.959840)
23. Oler G, Ebina KN, Michaluart P Jr, Kimura ET & Cerutti J 2005 Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clinical Endocrinology 62 509-511. (doi:10.1111/j.1365-2265.2005.02235.x)
24. Paulson L, Shindo M, Schuff K & Corless C 2012 The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Archives of Otolaryngology-Head & Neck Surgery 138 44-49. (doi:10.1001/archoto.2011.226)
25. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893. (doi:10.1158/0008-5472.CAN-09-0727)
26. Sargent R, LiVolsi V, Murphy J, Mantha G & Hunt JL 2006 BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocrine Pathology 17 235-241. (doi:10.1385/EP:17:3:235)
27. Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N & Fusco A 2012 Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 22 17-26. (doi:10.1089/thy.2011.0215)
28. Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW& Park SY 2012 Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Modern Pathology 25 938-948. (doi:10.1038/modpathol.2012.36)
29. Taniguchi K, Okami J, Kodama K, Higashiyama M & Kato K 2008 Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Science 99 929-935. (doi:10.1111/j.1349-7006.2008.00782.x)
30. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM et al. 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv 446 589-595. (doi:10.1007/s00428-005-1236-0)
31. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P et al. 2004 Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 89 4272-4279. (doi:10.1210/jc.2003-031870)
32. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B & Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. Journal of Clinical Endocrinology and Metabolism 90 5265-5269. (doi:10.1210/jc.2004-2353)
33. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 309 1493-1501. (doi:10.1001/jama.2013.3190)